All relevant results data are within the paper and its Supporting Information files. Individual-level data are available from dbGaP ([www.ncbi.nlm.nih.gov/gap](http://www.ncbi.nlm.nih.gov/gap)), accession numbers phs000227.v2.p3 (WHI), phs000559.v1.p1 (BioVU), phs000220.v1.p1 (MEC); or from [www.channing.harvard.edu/nhs](http://www.channing.harvard.edu/nhs) (NHS), and [www.hsph.harvard.edu/hpfs](http://www.hsph.harvard.edu/hpfs) (HPFS).

Introduction {#sec005}
============

As the most serious form of skin cancer, melanoma is a considerable public health burden. In 2013, there were an estimated 76,690 new diagnoses and 9,480 deaths from melanoma in the United States alone \[[@pone.0120491.ref001]\]. Ultraviolet (UV) radiation exposure is the largest environmental risk factor for melanoma, with an estimated 44--90% of melanoma attributable to sun exposure \[[@pone.0120491.ref002]\]. Other risk factors include artificial UV sources such as tanning beds \[[@pone.0120491.ref003]\], larger numbers of nevi, pigmentation traits (light versus dark hair, eye, and skin color), race/ethnicity (European versus non-European ancestry), skin response to UV exposure (burn versus tan), older age, and male sex \[[@pone.0120491.ref002]\]. Anatomic location of melanoma also tends to vary by sex, arising most commonly on the back, abdomen, and chest in males, and on the lower leg, hip, and thigh in females \[[@pone.0120491.ref002]\]. Females also appear to have lower risk of metastases and longer melanoma-specific survival than males \[[@pone.0120491.ref004]\]. In addition to environmental exposures, genetic risk factors have also been implicated for both familial and sporadic disease. Genome-wide association studies (GWAS) have successfully identified at least 11 susceptibility loci for melanoma \[[@pone.0120491.ref005], [@pone.0120491.ref006]\].

Several cancer susceptibility loci identified in GWAS, such as the 8q24 and *TERT-CLPTM1L* loci, have also been associated with numerous other cancer sites \[[@pone.0120491.ref007], [@pone.0120491.ref008]\]. Variants in the *TERT-CLPTM1L* region, for example, have been associated with basal cell carcinoma, melanoma, and glioma, as well as lung, bladder, prostate, pancreatic, and cervical cancers \[[@pone.0120491.ref008]--[@pone.0120491.ref010]\]. This provides evidence of pleiotropy, where a single genotype or locus is associated with multiple phenotypes. The existence of such pleiotropic effects suggests that there may be common mechanisms of carcinogenesis or disease susceptibility pathways across cancer phenotypes. Finding these effects can be useful for elucidating pathogenic mechanisms, improving disease classification, or targeting therapeutic intervention. While identifying and characterizing pleiotropy is important, the extent of pleiotropy has not been comprehensively explored. This study aims to evaluate single nucleotide polymorphisms (SNPs) associated with various cancers in previous GWAS for additional pleiotropic associations with melanoma. As melanoma risk and anatomic location have been shown to vary by sex \[[@pone.0120491.ref002]\], this study also evaluates whether any of these genetic associations may vary by sex as well.

Material and Methods {#sec006}
====================

Study Populations {#sec007}
-----------------

We analyzed 2,131 melanoma cases and 20,353 melanoma-free controls from five study populations. Three of these studies collaborated through their participation in the Population Architecture using Genomics and Epidemiology (PAGE) Study \[[@pone.0120491.ref011]\]: the Multiethnic Cohort (MEC) \[[@pone.0120491.ref012]\]; the Women's Health Initiative (WHI) \[[@pone.0120491.ref013]\]; and Epidemiological Architecture for Genes Linked to Environment (EAGLE), accessing BioVU, the Vanderbilt biorepository linked to de-identified electronic medical records \[[@pone.0120491.ref014], [@pone.0120491.ref015]\]. Two non-PAGE studies also contributed: the Nurses' Health Study (NHS) \[[@pone.0120491.ref016], [@pone.0120491.ref017]\] and the Health Professionals Follow-up Study (HPFS) \[[@pone.0120491.ref018]\]. NHS and WHI are female-only studies, and HPFS is a male-only study. Additional details on each of these studies are provided in the Supplemental Material ([S1 File](#pone.0120491.s001){ref-type="supplementary-material"}).

Each study performed a nested case-control analysis of melanoma using a subset of their overall study population. Invasive melanoma cases were defined as incident cases of melanoma in participants without a previous cancer diagnosis (except for non-melanoma skin cancer). EAGLE-BioVU also included prevalent melanoma cases diagnosed up to 5 years before entrance into the study, and some cases could have had prior cancers. Incident cancers were identified through follow-up questionnaires (WHI, NHS, HPFS), tumor and cancer surveillance registries (EAGLE-BioVU, MEC) and medical record entries (EAGLE-BioVU). Melanoma in situ cases were excluded in all studies.

Both matched and unmatched melanoma-free controls were used. In PAGE, a subset of controls were matched to melanoma cases on age (EAGLE-BioVU, MEC, WHI), sex (EAGLE-BioVU, MEC), enrollment date (WHI), race/ethnicity (EAGLE-BioVU, MEC, WHI), randomization arm (WHI), study site (MEC), or blood/urine collection factors (MEC). To improve power, each PAGE study also utilized additional unmatched melanoma-free controls, which had been matched to cases of other cancer types for similar PAGE analyses (sensitivity analyses showed no difference from including these additional controls). NHS and HPFS controls were not matched to melanoma cases, but came from previously matched nested case-control GWAS. Demographic and epidemiologic data were obtained according to individual study protocols. Due to low case numbers in other race/ethnicity groups, we restricted our analysis to participants of European ancestry.

The protocol for this study was approved by Institutional Review Boards at their respective institutions: BioVU was approved by the Vanderbilt Institutional Review Board; HPFS and NHS were approved by the Institutional Review Board at Brigham and Women's Hospital and the Harvard School of Public Health; MEC was approved by the Human Studies Program at the University of Hawaii and the Office for the Protection of Research Subjects at the University of Southern California; and WHI was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board. All participants of HPFS, NHS, MEC, and WHI provided written informed consent. All BioVU participants signed a ''consent-to-treatment" form informing them that anonymized genetic information from their discarded blood, along with de-identified EMR information, would be used for research; participants were given the choice to decline participation via an ''opt-out" box on the form.

SNP Selection and Genotyping {#sec008}
----------------------------

In PAGE, a custom panel of 189 SNPs associated with risk of various cancer types was selected and genotyped. SNPs were chosen based on the literature as of 2010 \[[@pone.0120491.ref011]\], as well as SNPs associated with cancer in the National Human Genome Research Institute GWAS catalog \[[@pone.0120491.ref019]\]. Each PAGE study genotyped a subset of this panel in order to maximize replication and generalization opportunities according to the characteristics of their study population. The risk allele for each SNP was defined as the allele associated with an increased risk of cancer, based on prior literature for the first reported association ([S1 Table](#pone.0120491.s002){ref-type="supplementary-material"}). Eight of these SNPs were originally identified as associated with melanoma risk, and were analyzed separately \[[@pone.0120491.ref020]\]. Several SNPs included in the PAGE panel were later reported to be associated with additional cancers, including melanoma. To remain consistent with their original reason for inclusion in the pleiotropy analyses, we analyzed all SNPs according to their initially reported cancer association. Thus, 181 SNPs were evaluated in this analysis.

Standard quality assurance and quality control measures were utilized to ensure genotyping quality. In PAGE, samples and SNPs were included based on call rates (≥90%), concordance of blinded replicates (\>98%), and no strong evidence of departure from Hardy-Weinberg equilibrium expectations (p\<0.001). Each laboratory also genotyped 360 HapMap samples to serve as cross-laboratory and cross-platform quality control samples \[[@pone.0120491.ref021]\].

In NHS and HPFS, participants had been previously genotyped in nested case-control GWAS of various outcomes ([S1 File](#pone.0120491.s001){ref-type="supplementary-material"}). For the melanoma GWAS, \>2.5 million SNPs were imputed based on NCBI build 35 of phase II HapMap CEU data using MACH. Only SNPs with an imputation quality r^2^\>0.95 in each study were included. Genotype information for the panel of 189 SNPs assembled by PAGE was available from this existing GWAS data.

To evaluate the pairwise correlation between SNPs in a region (such as *TPCN2*), we used the program SNAP \[[@pone.0120491.ref022]\]. As our study was restricted to those of European ancestry, we used the 1000 Genomes Pilot CEU data for obtaining r^2^ values between SNPs.

Statistical Analyses {#sec009}
--------------------

For each study we estimated the association between individual SNPs and risk of melanoma using unconditional logistic regression. SNPs were coded additively with 0, 1, 2 referring to the number of purported risk alleles (or the dosage for imputed SNPs), defined as the allele that increased the risk of cancer in the initial GWAS publication. Models were adjusted for age (all studies) and sex (EAGLE-BioVU and MEC only). In NHS and HPFS, models were also adjusted for each study's five most-significant GWAS-derived eigenvectors, using EIGENSTRAT \[[@pone.0120491.ref023]\], to account for population substructure. The three PAGE studies used ancestry informative markers to identify continental genetic ancestry of participants \[[@pone.0120491.ref024]\]. Since participants were already restricted to those of European ancestry, and GWAS-derived markers were not available, we did not adjust for principal components in these three studies.

Study-specific regression estimates were combined across studies using inverse-variance weighted fixed-effect meta-analysis. We calculated the heterogeneity p-values based on Cochran's Q statistic. Analyses were performed using Stata version 12 \[[@pone.0120491.ref025]\]. Because of multiple testing, we used a Bonferroni-corrected p-value threshold to determine the statistical significance of the overall association for each SNP with melanoma (p\<0.05/181 = 2.8x10^-4^). In order to evaluate for potential sex-specific genetic effects, we also evaluated the association between each SNP and melanoma risk stratified by sex. We performed meta-regression to obtain p-heterogeneity values for the difference between sex-specific regression estimates, using a significance threshold of p-heterogeneity\<0.05.

Results {#sec010}
=======

Demographic and epidemiologic characteristics of the study populations are provided in [Table 1](#pone.0120491.t001){ref-type="table"}. Since NHS and WHI are female-only studies, the overall analysis included roughly twice as many females as males. Melanoma cases were generally of similar age as controls (overall mean age of 65 in cases vs. 63 in controls).

10.1371/journal.pone.0120491.t001

###### Demographic characteristics of the five studies contributing to this analysis.

![](pone.0120491.t001){#pone.0120491.t001g}

                    Study     EAGLE-BioVU   HPFS    MEC     NHS     WHI     Total                                            
  ----------------- --------- ------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------- --------
  \# Participants   742       8,063         177     2,251   240     2,032   317     3,377   655     4,630   2,131   20,353   
  Sex               Males     445           4,351   177     2,251   149     1,059   0       0       0       0       771      7,661
                    Females   297           3,712   0       0       91      973     317     3,377   655     4,630   1,360    12,692
  Age               Mean      64            56      61      61      67      69      57      57      69      77      65       63
                    SD        12.4          15.6    9.3     8.5     9.5     8.5     6.8     6.7     7.1     7.1     11.0     14.4

In total we evaluated 181 cancer GWAS SNPs for an association with melanoma ([Fig. 1](#pone.0120491.g001){ref-type="fig"}). Two SNPs were statistically significantly associated with melanoma: rs4975616 and rs401681, both in the *TERT/CLPTM1L* locus (Odds Ratio (OR) = 0.87, 95% Confidence Interval (CI): 0.81--0.93, p-values \< 3.7x10^-5^, [Table 2a](#pone.0120491.t002){ref-type="table"}). Both of these SNPs were originally identified in GWAS of lung cancer, and then later additionally associated with melanoma \[[@pone.0120491.ref008], [@pone.0120491.ref026]\]. Of note, our results are consistent with previous studies showing that these SNPs have pleiotropic effects in opposite directions for different cancer types. Specifically, for both SNPs the allele associated with an increased risk of lung cancer appears to also be associated with a decreased risk of melanoma.

![Pleiotropy-colored Manhattan plot.\
This plot shows the inverse log of the P-value for the association between melanoma and SNPs previously associated with cancer. The solid line represents the Bonferroni-corrected significance threshold for this analysis (0.05/181 = 2.8x10^-4^). Each association is colored according to the cancer for which the SNP was originally reported, and placed on the x-axis according to its genomic position.](pone.0120491.g001){#pone.0120491.g001}

10.1371/journal.pone.0120491.t002

###### Association between cancer GWAS SNPs and melanoma.

![](pone.0120491.t002){#pone.0120491.t002g}

  **Table 2a)**                                                                                            
  --------------- ---------------- ------- ------------- -------- --- ------ -------------- -------------- ------
  rs4975616       *TERT/CLPTM1L*   5 / A   Lung cancer   22,135   5   0.87   (0.81--0.93)   **2.30E-05**   0.78
  rs401681        *TERT/CLPTM1L*   5 / C   Lung cancer   22,109   5   0.87   (0.81--0.93)   **3.65E-05**   0.70

  **Table 2b)**                                                                                                                      
  --------------- ---------------------------- -------- ------------------------------ -------- --- ------ -------------- ---------- ------
  rs7117034       *TPCN2*, *MYEOV* (near)      11 / T   Prostate cancer                10,675   2   1.23   (1.10--1.37)   3.67E-04   0.55
  rs402710        *CLPTM1L* (intronic)         5 / C    Lung cancer                    15,991   3   0.87   (0.81--0.94)   7.74E-04   0.04
  rs12155172      *ABCB5* (near)               7 / A    Prostate cancer                10,703   2   1.19   (1.06--1.33)   3.38E-03   0.61
  rs13281615      *MYC*, *POU5F1B* (near)      8 / T    Breast cancer                  22,138   5   1.11   (1.03--1.18)   3.44E-03   0.20
  rs31489         *CLPTM1L* (intronic)         5 / C    Lung cancer                    14,004   2   0.89   (0.82--0.96)   4.18E-03   0.33
  rs12418451      *TPCN2*, *MYEOV* (near)      11 / A   Prostate cancer                22,053   5   1.11   (1.03--1.19)   5.03E-03   0.30
  rs505922        *ABO* (intronic)             9 / C    Pancreatic cancer              13,339   4   0.89   (0.82--0.98)   0.013      0.40
  rs710521        *LEPREL1*, *TP63* (near)     3 / A    Urinary bladder cancer         9,608    3   1.13   (1.01--1.27)   0.028      0.55
  rs7176508       *RPLP1*, *GEMIN8P1* (near)   15 / A   Chronic lymphocytic leukemia   11,395   3   1.10   (1.00--1.21)   0.039      0.78
  rs10411210      *RHPN2* (intronic)           19 / C   Colorectal cancer              15,971   3   1.14   (1.00--1.30)   0.046      0.68

2a) SNPs showing a statistically significant association with melanoma at a Bonferroni-corrected threshold of 0.05/181 = 2.8x10^-4^.

2b) SNPs showing a marginal association with melanoma at p\<0.05.

No other SNP was associated with melanoma below our Bonferroni-corrected statistical significance threshold of p\<2.8x10^-4^, though 10 additional SNPs had p-values below 0.05 ([Table 2b](#pone.0120491.t002){ref-type="table"}). These SNPs were previously associated with seven different cancers. Seven of these ten SNPs showed an increased risk for melanoma in the same direction as the previously associated cancer (OR = 1.10--1.23). The other three of these SNPs showed a decreased risk of melanoma: two *TERT/CLPTM1L* SNPs previously associated with lung cancer (rs402710, OR = 0.87; rs31489, OR = 0.89) and one *ABO* SNP previously associated with pancreatic cancer (rs505922, OR = 0.89). Due to multiple testing, some (or all) of these marginal findings could be due to chance (expect 0.05\*181 = 9.05), though correlated SNPs may not represent independent tests. Results for all 181 SNPs are provided in [S2 Table](#pone.0120491.s003){ref-type="supplementary-material"}.

In the sex-stratified analyses, one additional SNP, rs12418451 (near *TPCN2*), nearly reached statistical significance in males (p = 7.96x10^-4^), but not in females or overall (p-heterogeneity = 0.04, [Table 3a](#pone.0120491.t003){ref-type="table"}), and also showed a larger effect in males (OR = 1.22, 95% CI: 1.09--1.37) than females (OR = 1.05, 95% CI: 0.96--1.14). Four other nearby (40--60kb away) but uncorrelated (r^2^ with rs12418451 \< 0.2) SNPs in this region also showed a trend of stronger effects in males than females, though none suggested a statistically significant difference (p-heterogeneity\>0.05, [Table 3b](#pone.0120491.t003){ref-type="table"}). In total, 12 additional SNPs (13 total including rs12418451) showed between-sex heterogeneity p-values below 0.05, slightly more than we expected by chance (0.05\*181 = 9.05), but the association was not significant in either sex stratum. Sex-stratified results for all SNPs are provided in [S3 Table](#pone.0120491.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0120491.t003

###### Association between SNPs in the *TPCN2/MYEOV* region and melanoma.
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  Table 3a)    p-heterogeneity                                                                           
  ------------ ------------------------- ---------- --- -------- ------ -------------- ---------- ------ ----------
  rs12418451   *TPCN2*, *MYEOV* (near)   Combined   5   22,053   1.11   (1.03--1.19)   5.03E-03   0.30   
               11 / A                    Male       3   8,213    1.22   (1.09--1.37)   7.96E-04   0.21   **0.04**
               Prostate cancer           Female     4   13,840   1.05   (0.96--1.14)   0.33       0.42   

  **Table 3b)**   p-heterogeneity                                                                               
  --------------- ------------------------- ---------- --- -------- ------ -------------- ---------- ---------- -------
  rs11228565      *TPCN2*, *MYEOV* (near)   Combined   2   14,026   1.06   (0.96--1.17)   0.22       4.38E-04   
  r^2^ = 0.13     11 / A                    Male       1   4,756    1.21   (1.03--1.42)   0.02       .          0.051
                  Prostate cancer           Female     2   9,270    0.99   (0.87--1.12)   0.84       3.53E-03   
  rs10896449      *TPCN2*, *MYEOV* (near)   Combined   5   22,092   1.05   (0.99--1.12)   0.12       0.53       
  r^2^ = 0.07     11 / G                    Male       3   8,221    1.10   (0.99--1.23)   0.07       0.86       0.28
                  Prostate cancer           Female     4   13,871   1.02   (0.94--1.11)   0.58       0.34       
  rs7117034       *TPCN2*, *MYEOV* (near)   Combined   2   10,675   1.23   (1.1--1.37)    3.67E-04   0.55       
  r^2^ = 0.13     11 / T                    Male       2   5,775    1.26   (1.09--1.45)   2.07E-03   0.20       0.62
                  Prostate cancer           Female     2   4,900    1.18   (0.99--1.42)   0.07       0.44       
  rs7931342       *TPCN2*, *MYEOV* (near)   Combined   4   13,336   1.03   (0.95--1.12)   0.48       0.68       
  r^2^ = 0.05     11 / G                    Male       2   3,451    1.05   (0.89--1.25)   0.56       0.76       0.78
                  Prostate cancer           Female     3   9,885    1.02   (0.93--1.13)   0.63       0.37       

3a) Association between SNP rs12418451 melanoma, both overall and stratified by sex.

3b) Four additional SNPs within the same locus as rs12418451, shown for comparison (r^2^ with rs12418451 \< 0.13 in 1000G CEU).

Discussion {#sec011}
==========

We replicated previously reported associations with melanoma for two SNPs in the *TERT-CLPTM1L* region. These SNPs were previously shown to demonstrate pleiotropic effects in opposing directions, with decreased risk for melanoma but increased risk for lung and other cancers. We also observed a marginally significant association with melanoma in *TPCN2*, suggesting a potential male-specific pleiotropic association with both melanoma and prostate cancer. Notably, none of the other cancer susceptibility SNPs evaluated showed evidence for a pleiotropic association with melanoma.

The two SNPs demonstrating a significant association with melanoma (rs401681 and rs4975616) are located in the *TERT-CLPTM1L* locus, which contains variants associated with a number of different cancers. The pleiotropic effects of variants in this region have been well established \[[@pone.0120491.ref008]--[@pone.0120491.ref010]\], and our findings are consistent with previous reports associating cancer risk variants in this region with decreased risk of melanoma \[[@pone.0120491.ref008], [@pone.0120491.ref026], [@pone.0120491.ref027]\]. Specifically, the *C* allele of rs401681 has been associated with an increased risk of lung cancer \[[@pone.0120491.ref028]\], basal cell carcinoma \[[@pone.0120491.ref027]\], bladder cancer, prostate cancer, and cervical cancer \[[@pone.0120491.ref008]\]. This same allele has also been associated with a decreased risk of melanoma \[[@pone.0120491.ref008], [@pone.0120491.ref027]\] and pancreatic cancer \[[@pone.0120491.ref029]\]. The other SNP in this region that was statistically significant in our study, rs4975616 (*A* allele), has also been previously associated with an increased risk of lung cancer \[[@pone.0120491.ref028], [@pone.0120491.ref030]\] and a decreased risk of melanoma \[[@pone.0120491.ref026]\]. While not reaching our Bonferroni cutoff, two other SNPs in this region were also marginally associated with decreased risk of melanoma in our study: rs402710 (*C* allele, p = 7.74x10^-4^) and rs31489 (*C* allele, p = 4.18x10^-3^). These alleles have also been previously associated with increased risk of lung cancer \[[@pone.0120491.ref009]\], as well as increased risk of bladder cancer (rs402710) and decreased risk of testicular or pancreatic cancer (rs31489) \[[@pone.0120491.ref010]\]. These four SNPs are all located within the *CLPTM1L* gene and are in relatively high linkage disequilibrium with each other (r^2^\>0.57; from 1000 Genomes Project pilot CEU data using SNAP \[[@pone.0120491.ref022]\]). Two nearby SNPs within the *TERT* gene were not associated with melanoma (p\>0.39), and were not correlated with any of the four *CLPTM1L* SNPs (r^2^\<0.07). Taken together, our findings provide further evidence of pleiotropic effects in opposite directions in the *TERT-CLPTM1L* region, where variants associated with increased risk for lung and other cancers are simultaneously associated with reduced melanoma risk.

In our sex-stratified analyses, we identified one SNP (rs12418451) that demonstrated a marginally significant association with melanoma in males, but not in either the female or overall analyses. Previously associated with prostate cancer \[[@pone.0120491.ref031]\], this SNP is located \~77kb downstream of *TPCN2* and \~126kb upstream of *MYEOV*. The proximity of this SNP to these other genes provides biological plausibility for an association with melanoma. The nearby *TPCN2* (two-pore segment channel 2) encodes a putative cation-selective ion channel that releases Ca^2+^ from acidic organelles \[[@pone.0120491.ref032]\]. Similarly to other ion transport genes associated with melanoma, such as *SLC45A2*, variants in *TPCN2* may impact melanogenesis through pH regulation \[[@pone.0120491.ref033]\]. Indeed, two coding variants in *TPCN2* have been associated with pigmentation traits (blond versus brown hair color \[[@pone.0120491.ref034]\]), though neither are highly correlated with rs12418451 (r^2^\<0.07). A later study did not find either of these two *TPCN2* SNPs to be associated with melanoma (p\>0.12), though they did not stratify by sex \[[@pone.0120491.ref035]\].

SNP rs12418451 is also \~126 kb upstream of *MYEOV*, an oncogene that includes variants implicated for multiple cancers, including multiple myeloma, breast cancer, colon cancer, and esophageal squamous cell carcinoma \[[@pone.0120491.ref036]\]. A proxy of rs12418451 is also one of three independent loci in this region associated with prostate cancer \[[@pone.0120491.ref037]\]. Another study evaluating this region for prostate cancer identified an interaction between rs12418451 and rs784411 in *CEP152*, a centrosomal protein shown to function as a regulator of genomic integrity and cellular response to DNA damage \[[@pone.0120491.ref036]\]. In our study, a second SNP in this region (rs7117034, \~117kb downstream of *TPCN2*) was also marginally associated with melanoma risk overall (p = 3.7x10^-4^). While this SNP also suggested a stronger effect in males than females (OR = 1.26 and 1.18, respectively), this difference was not statistically significant (p-heterogeneity = 0.62). Together, our findings identify a potentially novel pleiotropic finding for a sex-specific association between rs12418452 and melanoma, and highlight a new locus for melanoma with plausible biologic function.

Our sex-specific finding for SNP rs12418451 also raises interesting questions regarding potential sex differences in the relationships between ion transport, pigmentation, and melanoma. We recently reported a sex difference in association with melanoma for rs16891982 in *SLC45A2*, another SNP in a solute-carrier gene associated with pigmentation \[[@pone.0120491.ref020]\]. These and other melanosome ion transporter proteins have demonstrated the functional importance of ion and small molecule transport to melanogenesis and the pigmentation pathway \[[@pone.0120491.ref038], [@pone.0120491.ref039]\]. Though they transport different molecules, these SNPs in *SLC45A2* and near *TPCN2* both demonstrated associations with melanoma that were larger in males than in females.

Previous evidence that skin pigmentation processes can be up- or down-regulated by sex hormones provides biological plausibility for such a difference. Findings in a study of the hyperpigmentation condition melasma, for example, supported the role of several ion transporters in the estrogen-induced expression of tyrosinase \[[@pone.0120491.ref040]\]. Another study found that androgens can inhibit tyrosinase activity \[[@pone.0120491.ref041]\]. As the rate-limiting enzyme in melanin synthesis, the regulation of tyrosinase activity impacts skin pigmentation through the levels of eumelanin and pheomelanin produced \[[@pone.0120491.ref033]\]. As males and females differ in their circulating levels of sex hormones, it is feasible that hormones impact ion exchange or tyrosinase activity in a way that modifies the effect of these variants on melanoma risk, perhaps through alterations to melanogenesis or skin pigmentation. As such, variants in other ion transport genes similar to *TPCN2* and *SLC45A2* might also be expected to impact pigmentation and melanoma risk. Interestingly, sex differences in the genetic effect of solute carrier genes have also been seen for other phenotypes, such as *LYPLAL1/SLC30A10* with waist-hip ratio \[[@pone.0120491.ref042]\]. While suggestive, further research to evaluate these potential sex differences for melanoma risk is needed.

The strengths of this study stem from the collaboration of five large studies, which together provide sizable samples to evaluate the association of melanoma with cancer GWAS SNPs. A potential limitation is that three of these studies were conducted only in males (HPFS) or females (NHS, WHI). Since not all SNPs were available in all studies, sample sizes also varied by SNP depending on which studies had that particular SNP available. These differences in sample size may have reduced our ability to detect an association with melanoma for some SNPs. However, 97% of SNPs were available in at least two studies (and 75% in at least three), and most overall analyses were large (mean number of participants available per SNP 14,836, range 1,925--22,141). An additional limitation is that we were unable to test whether some of our findings are independently associated with melanoma, or are due to an association with pigmentation characteristics. Unfortunately, data were not available to evaluate these associations according to skin/hair pigmentation or anatomical location. Additional work will be needed to explore the relationships between these genetic variants, pigmentation characteristics, and melanoma.

Conclusions {#sec012}
===========

In summary, we provided confirmatory evidence of pleiotropic associations with melanoma for two SNPs in *TERT-CLPTM1L* and identified a potentially novel sex-specific association for a SNP near *TPCN2/MYEOV*. Variants in the *TERT-CLPTM1L* locus demonstrated pleiotropic effects in opposite directions from other cancers, where the allele previously associated with increased risk of lung and other cancers demonstrated an association with decreased risk of melanoma in our study. Additionally, we were able to provide some evidence of an association with melanoma for one SNP near solute-carrier gene *TPCN2* that showed potential differences in effect by sex, with a larger effect in males than females. Previously associated with increased risk of prostate cancer, this SNP demonstrated a potentially pleiotropic effect of increased risk of melanoma. While this latter finding did not reach statistical significance, it is a biologically plausible candidate for follow-up studies.
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